NCI | Technology Transfer

IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA
PHOSPHODIESTERASE I (TDP1) INHIBITORS

Read more about IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS

European Patent
22705222.2
Filed on 2023-08-08

IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA
PHOSPHODIESTERASE I (TDP1) INHIBITORS

Read more about IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS

US Application 18/262,779
Filed on 2023-07-25

ANTIVIRAL STRUCTURALLY-STABILIZED EBOLAVIRUS PEPTIDES AND USES THEREOF

Read more about ANTIVIRAL STRUCTURALLY-STABILIZED EBOLAVIRUS PEPTIDES AND USES THEREOF

US Application 18/035,427
Filed on 2023-05-04

METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES

Read more about METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES

China
202310701331.7
Filed on 2023-06-13

CD25-SPECIFIC ANTIBODIES AND USES THEREOF

Read more about CD25-SPECIFIC ANTIBODIES AND USES THEREOF

Patent Cooperation Treaty
PCT/US2023/069461
Filed on 2023-06-30

METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION

Read more about METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION

European Patent
23185846.5
Filed on 2023-07-17

HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION

Read more about HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION

Hong Kong
62023074794.6
Filed on 2023-06-21

ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS

Read more about ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS

Japan
2023-091878
Filed on 2023-06-02

ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS

Read more about ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS

US Application 18/323,493
Filed on 2023-05-25

Anti-Viral Compositions And Methods Of Making And Using

Read more about Anti-Viral Compositions And Methods Of Making And Using

US Application 17/641,264
Filed on 2022-03-08

Subscribe to NCI